Form 4: Revolution Medicines Executive Acquires Shares and Stock Options

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired shares and stock options on March 1, 2025.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, filed a Form 4.
• On March 1, 2025, Kelsey acquired 36,600 shares of common stock at $0 and 128,100 stock options with an exercise price of $40.74.
• Following the transaction, Kelsey directly owns 296,345 shares of common stock, including 113,926 restricted stock units.
• The stock options vest monthly from March 1, 2025, over four years, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants, indicating standard executive compensation practices. The executive's increased stake could be seen as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of shares and stock options by a key executive signals confidence in the company's future.

Future Outlook

The vesting schedule of the stock options indicates a long-term commitment from the executive, with full vesting occurring over four years from March 1, 2025, contingent on continued service.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency into the actions of company executives and their confidence in the company's prospects. These filings are closely watched by investors for signals about a company's health and future performance.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules, like the four-year monthly vesting described, are standard practice to incentivize long-term commitment.
• Comparable companies such as Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.

Stakeholder Impact

• The transaction could positively influence shareholder sentiment, as it demonstrates the executive's increased alignment with the company's success.
• Employees may view the executive's increased stake as a positive sign for the company's future.

Key Dates